97 related articles for article (PubMed ID: 6401589)
1. The effect of surgery and chemotherapy on blood NK cell activity in patients with ovarian cancer.
Lukomska B; Olszewski WL; Engeset A; Kolstad P
Cancer; 1983 Feb; 51(3):465-9. PubMed ID: 6401589
[TBL] [Abstract][Full Text] [Related]
2. Augmented natural killer activity in ovarian cancer patients treated with cimetidine.
Kikuchi Y; Oomori K; Kizawa I; Kato K
Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1037-43. PubMed ID: 3780810
[TBL] [Abstract][Full Text] [Related]
3. The relationship of chemotherapeutic and endocrine intervention on natural killer cell activity in human breast cancer.
Brenner BG; Margolese RG
Cancer; 1991 Aug; 68(3):482-8. PubMed ID: 2065267
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing ovarian cancer survival after chemotherapy.
Webb MJ; Malkasian GD; Jorgensen EO
Obstet Gynecol; 1974 Oct; 44(4):564-70. PubMed ID: 4413425
[No Abstract] [Full Text] [Related]
5. [Observation on natural killer cell activity in gastric cancer patients and effect of nonspecific immunopotentiator administration on its postoperative reduction].
Oshita H; Saji S; Sugiyama Y; Tanemura H; Sakata K; Tanaka S; Ito T
Nihon Geka Gakkai Zasshi; 1985 Oct; 86(10):1417-25. PubMed ID: 4079897
[TBL] [Abstract][Full Text] [Related]
6. Effect of human fibroblast interferon on the cytotoxic activity of natural killer cells and lymphocytes against autochthonous and allogeneic tumor cells.
Ezaki K; Okabe K; Domyo M; Abe K; Kubokawa C; Ogawa M
Gan; 1983 Oct; 74(5):723-9. PubMed ID: 6227516
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cell activity and progression-free survival in ovarian cancer.
Garzetti GG; Cignitti M; Ciavattini A; Fabris N; Romanini C
Gynecol Obstet Invest; 1993; 35(2):118-20. PubMed ID: 8383627
[TBL] [Abstract][Full Text] [Related]
8. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
9. The effect of cimetidine on natural killer activity of peripheral blood lymphocytes of patients with ovarian carcinoma.
Kikuchi Y; Oomori K; Kizawa I; Kato K
Jpn J Clin Oncol; 1985 Jun; 15(2):377-83. PubMed ID: 3839542
[TBL] [Abstract][Full Text] [Related]
10. Mirimostim (macrophage colony-stimulating factor; M-CSF) improves chemotherapy-induced impaired natural killer cell activity, Th1/Th2 balance, and granulocyte function.
Hidaka T; Akada S; Teranishi A; Morikawa H; Sato S; Yoshida Y; Yajima A; Yaegashi N; Okamura K; Saito S
Cancer Sci; 2003 Sep; 94(9):814-20. PubMed ID: 12967481
[TBL] [Abstract][Full Text] [Related]
11. Effect of surgery on pancreatic tumor-dependent lymphocyte asset: modulation of natural killer cell frequency and cytotoxic function.
Iannone F; Porzia A; Peruzzi G; Birarelli P; Milana B; Sacco L; Dinatale G; Peparini N; Prezioso G; Battella S; Caronna R; Morrone S; Palmieri G; Mainiero F; Chirletti P
Pancreas; 2015 Apr; 44(3):386-93. PubMed ID: 25621568
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy in the treatment of cancer of the ovary.
Smith JP; Rutledge F
Am J Obstet Gynecol; 1970 Jul; 107(5):691-703. PubMed ID: 4316665
[No Abstract] [Full Text] [Related]
13. Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation.
Garzetti GG; Ciavattini A; Muzzioli M; Romanini C
Cancer; 1999 May; 85(10):2226-31. PubMed ID: 10326702
[TBL] [Abstract][Full Text] [Related]
14. [The effect of various factors on the results of chemotherapy in patients with recurrent ovarian serous cystadenocarcinoma].
Dzhilavian GA; Vinokurov VL
Vopr Onkol; 1984; 30(3):16-21. PubMed ID: 6424327
[TBL] [Abstract][Full Text] [Related]
15. High dose thiotepa in ovarian cancer.
Shetty PA; Kurkure PA; Pai VR; Gohokar D; Pai S; Shinde SR; D'Souza LJ; Sampat MB
Indian J Cancer; 1985 Mar; 22(1):33-7. PubMed ID: 3939232
[No Abstract] [Full Text] [Related]
16. Management of ovarian carcinoma: a review of 14 years' experience at Beth Israel Hospital.
Blinick G; Kabakow B; Antopol W; Wallach RC
Mt Sinai J Med; 1972; 39(5):447-57. PubMed ID: 4628079
[No Abstract] [Full Text] [Related]
17. [Chemotherapy of patients with recurring malignant tumors of the ovaries].
Kotova DG; Vinokurov VL
Vopr Onkol; 1975; 21(4):19-23. PubMed ID: 812259
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation.
Arbour S; Toupin S; Bélanger R; Gyger M; Hallé JP; Perreault C; Roy DC
Bone Marrow Transplant; 1996 Mar; 17(3):315-22. PubMed ID: 8704680
[TBL] [Abstract][Full Text] [Related]
19. Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.
Pandey V; Oyer JL; Igarashi RY; Gitto SB; Copik AJ; Altomare DA
Oncotarget; 2016 Feb; 7(6):7318-28. PubMed ID: 26802025
[TBL] [Abstract][Full Text] [Related]
20. Social support, psychological distress, and natural killer cell activity in ovarian cancer.
Lutgendorf SK; Sood AK; Anderson B; McGinn S; Maiseri H; Dao M; Sorosky JI; De Geest K; Ritchie J; Lubaroff DM
J Clin Oncol; 2005 Oct; 23(28):7105-13. PubMed ID: 16192594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
